Aspiriant LLC Purchases 1,316 Shares of Pfizer Inc. (NYSE:PFE)

Aspiriant LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 5.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 25,870 shares of the biopharmaceutical company’s stock after acquiring an additional 1,316 shares during the period. Aspiriant LLC’s holdings in Pfizer were worth $930,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. 1 North Wealth Services LLC purchased a new stake in shares of Pfizer in the 3rd quarter valued at $29,000. Evolution Wealth Advisors LLC purchased a new stake in shares of Pfizer in the 2nd quarter valued at $34,000. IMA Wealth Inc. boosted its stake in shares of Pfizer by 144.5% in the 2nd quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 477 shares in the last quarter. B & T Capital Management DBA Alpha Capital Management purchased a new stake in shares of Pfizer in the 3rd quarter valued at $36,000. Finally, Sageworth Trust Co purchased a new stake in shares of Pfizer in the 3rd quarter valued at $44,000. 71.52% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have recently issued reports on the stock. Bank of America assumed coverage on shares of Pfizer in a research note on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 price objective for the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Pfizer in a research note on Tuesday, October 29th. UBS Group reaffirmed a “neutral” rating and issued a $43.00 price objective on shares of Pfizer in a research note on Monday, August 5th. Credit Suisse Group reaffirmed a “hold” rating and issued a $41.30 price objective on shares of Pfizer in a research note on Wednesday. Finally, DZ Bank raised shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price objective for the company in a research note on Wednesday, August 28th. Nine investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Pfizer presently has a consensus rating of “Hold” and a consensus price target of $44.02.

Shares of PFE opened at $37.05 on Friday. The stock has a market capitalization of $207.30 billion, a P/E ratio of 12.35, a PEG ratio of 2.11 and a beta of 0.67. The company has a quick ratio of 1.21, a current ratio of 1.47 and a debt-to-equity ratio of 0.60. The firm has a fifty day simple moving average of $36.62 and a two-hundred day simple moving average of $39.26. Pfizer Inc. has a twelve month low of $33.97 and a twelve month high of $46.47.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.13. The business had revenue of $12.68 billion during the quarter, compared to analysts’ expectations of $12.37 billion. Pfizer had a net margin of 30.57% and a return on equity of 28.61%. The firm’s revenue for the quarter was down 4.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.78 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.36 per share. The ex-dividend date is Thursday, November 7th. This represents a $1.44 annualized dividend and a yield of 3.89%. Pfizer’s payout ratio is currently 48.00%.

In other news, major shareholder Pfizer Inc purchased 50,000 shares of the company’s stock in a transaction on Tuesday, September 17th. The stock was acquired at an average price of $18.00 per share, with a total value of $900,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Scott Gottlieb purchased 3,000 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were purchased at an average cost of $34.72 per share, with a total value of $104,160.00. Following the transaction, the director now directly owns 3,000 shares in the company, valued at $104,160. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: Compound Interest and Why It Matters When Investing

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Leave a Reply

Your email address will not be published. Required fields are marked *

*